

The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books

Oct 1, 2019 • 1h 4min
Ep53: Phil Sharp
MIT biologist Phil Sharp on his early career.

Sep 18, 2019 • 46min
Ep52: Bruce Carter
Bruce Carter on developing a new tuberculosis drug.

Sep 3, 2019 • 1h 3min
Ep51: Ted Love
Ted Love of Global Blood Therapeutics on a new drug for sickle cell disease

Aug 20, 2019 • 1h 5min
Ep50: Joel Marcus
Joel Marcus, chairman of Alexandria Real Estate Equities, on building in biotech clusters.

Aug 8, 2019 • 1h 5min
Ep49: Janelle Anderson
Janelle Anderson on venture capital and off-the-shelf cell therapy at Century Therapeutics

Jul 11, 2019 • 1h 2min
Ep48: Cindy Perettie
Cindy Perettie of Foundation Medicine on genomic analysis for cancer.

Jul 2, 2019 • 1h 11min
Ep47: Laura Shawver
Laura Shawver on synthetic biology engineering of cancer drugs.

Jun 12, 2019 • 1h 7min
Ep46: Liz O'Day
Liz O'Day on metabolite signatures for predicting cancer drug response.

May 22, 2019 • 1h 11min
Ep45: Jay Bradner
Jay Bradner, president of Novartis Institutes for Biomedical Research, on his journey from open biology advocate to pharma leadership.

May 9, 2019 • 1h 12min
Ep44: Sheila Gujrathi
Sheila Gujrathi, CEO of Gossamer Bio, immunologic drug developer